Published in Nat Rev Drug Discov on September 06, 2013
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol (2014) 1.09
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine (2015) 0.94
Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. Eur Radiol (2014) 0.89
European Medicines Agency initiatives and perspectives on pharmacogenomics. Br J Clin Pharmacol (2014) 0.79
Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data. Front Pharmacol (2016) 0.78
Analytical strategies for discovery and replication of genetic effects in pharmacogenomic studies. Pharmgenomics Pers Med (2014) 0.75
Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. Genet Med (2015) 0.75
Advances in the treatment of aortic valve disease: is it time for companion diagnostics? Curr Opin Pediatr (2014) 0.75
Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission. Exp Hematol Oncol (2017) 0.75
Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm. Eur J Clin Pharmacol (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics (2003) 6.31
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Aff (Millwood) (2011) 3.58
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res (2007) 2.50
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol (2013) 2.36
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol (2012) 2.26
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med (2013) 2.26
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park) (2014) 2.12
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res (2003) 2.04
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol (2006) 1.99
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res (2005) 1.97
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer (2003) 1.91
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc (2007) 1.89
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84